

FILING BY "EXPRESS MAIL" UNDER 37 CFR 1.10

EV54015495305

Express Mail Label Number

October 8, 2004

Date of Deposit

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE PCT NATIONAL STAGE APPLICATION OF

OWEN ET AL.

INTERNATIONAL APPLICATION NO: PCT/EP03/00154

FILED: 9 JANUARY 2003

U.S. APPLICATION NO: 10/500,200

35 USC §371 DATE:

FOR: COMBINATION TREATMENTS FOR ALLERGIC DISEASE
COMPRISING ADMINISTERING AN ANTI-IGE ANTIBODY AND
ANTIALLERGIC COMPOUND**MS: Amendment**Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450INFORMATION DISCLOSURE STATEMENT

Sir:

This paper is being filed within three months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 of the international application. Therefore, no fees are required. If a fee is deemed to be required, the Commissioner is hereby authorized to charge such fee to Deposit Account No. 19-0134.

In accordance with 37 C.F.R. §1.56, applicants wish to call the Examiner's attention to the references cited on the attached form(s) PTO-1449.


The listed references were cited in the international stage search report. Since these references are of record in the instant PCT application PCT/EP03/00154, copies are not enclosed herewith.

The Examiner is requested to consider the foregoing information in relation to this application and indicate that each reference was considered by returning a copy of the initialed PTO 1449 form(s).

Novartis
Corporate Intellectual Property
One Health Plaza, Building 430
East Hanover, NJ 07936-1080
(862) 778-2614

Date: 10/8/04

Respectfully submitted,

Gregory C. Houghton
Attorney for Applicants
Reg. No. 47,666

INFORMATION DISCLOSURE CITATION

(Use several sheets if necessary)

ATTY. DOCKET
DC/4-32002A
APPLICATION NO.APPLICANT
OWEN ET AL.
FILING DATE

Group

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE
	AA						
	AB						
	AC						
	AD						
	AE						
	AF						
	AG						
	AH						
	AI						
	AJ						
	AK						
	AL						

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	OFFICE	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AM	00/16804	3/30/00	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AN	01/90110	11/29/01	WO			<input type="checkbox"/>	<input type="checkbox"/>
	AO						<input type="checkbox"/>	<input type="checkbox"/>
	AP						<input type="checkbox"/>	<input type="checkbox"/>
	AQ						<input type="checkbox"/>	<input type="checkbox"/>

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent pages, Etc.)

	AR	Busse et al., "Omalizumab, Anti-IgE Recombinant Humanized Monoclonal Antibody, for the Treatment of Severe Allergic Asthma", Journal of Allergy and Clinical Immunology, Vol. 108, No. 2, pp. 184-190 (2001).
	AS	Heusser et al., "Therapeutic Potential of Anti-IgE Antibodies", Current Opinion in Immunology, Vol. 9, No. 6, pp. 805-813 (1997).
	AT	Kuehr et al., "Omalizumab (Xolair(R) RHUMAB-E25) in Children with Seasonal Allergic Rhinitis to Birch and Grass Pollen: Superior Efficacy of Xolair Plus Specific Immunotherapy over Specific Immunotherapy Alone During Grass Pollen Season", Allergy, Vol. 56, No. Suppl. 68, pp. 93-94 (2001).

EXAMINER

DATE CONSIDERED

*EXAMINER: Initial of reference considered, whether or not citation is in conformance with MPEP 609: Draw a line through citation if not in conformance and not considered. Include a copy of this form with the next communication to applicant.